



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10/C
ALD
1-18-02

TECH CENTER 1600/2900

DEC 27 2001

RECEIVED

In re the Application of:

Maryvonne CHARLOT et al.

Serial No.: 09/605,054

Group Art Unit: 1619

Filed: June 28, 2000

Examiner: A. Berman

For: SLOW-RELEASE PHARMACEUTICAL FORMULATIONS CONTAINING
MIZOLASTINE

AMENDMENT UNDER RULE 111

Honorable Commissioner of Patents
Washington, D.C. 20231

Dear Sir:

Responsive to the Office Action (Paper No. 8) of June 20, 2001, kindly amend the claims of the above-identified application as follows:

IN THE CLAIMS

21. (Amended) A coated sustained release tablet, consisting essentially of from 0.5% to 12% by weight of mizolastine, a fatty matrix, an organic acid and a coating.

G 22. (Amended) A coated sustained release tablet according to claim 21, which has a dissolution profile which is pH independent.

23. (Amended) A coated sustained release tablet, consisting essentially of mizolastine, a fatty matrix, an organic acid, and a coating, the coated tablet having a dissolution profile which is pH independent, the organic acid being a member selected